Morningside
VC Fund
Shanghai, China
Morningside is a VC fund in Shanghai focused on Biotechnology and Health Care. Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically. Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology. Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
- Total investments:
- 155
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Morningside invests in
Stages Morningside invests in
Countries Morningside invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 43 (28%)
- Health Care 40 (26%)
- Medical 23 (15%)
- Therapeutics 16 (10%)
- Software 15 (10%)
Stage
- Series B 45 (29%)
- Series A 41 (26%)
- Series C 20 (13%)
- Seed 13 (8%)
- Series D 12 (8%)
Country
- United States 65 (42%)
- China 36 (23%)
- United Kingdom 10 (6%)
- Canada 4 (3%)
- India 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gerald Chan
Co-founded
|
Co-founded | Total investments: 25 | Find email | |
Isaac Cheng
Investment Professional
|
Investment Professional | Total investments: 12 | Find email | |
Richard Liu
General Partner
|
General Partner | Total investments: 27 | Find email | |
Ronnie Chan
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
Stephanie O'Brien
Partner
|
Partner | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DeweyLearn
|
DeweyLearn provides an AI-driven learning analytics platform that observes and analyzes real learning interactions across classrooms and online environments. The platform combines audio, video, and learning data to interpret engagement, collaboration, and skill development for individual learners and groups. DeweyLearn is trained on eachorganization’s curriculum, domain knowledge, and assessment rubrics to deliver targeted, context-aware feedback. Educators and trainers use the system to monitor participation, assess mastery, and receive confidential guidance on instructional practices. Institutions apply DeweyLearn to support corporate training, higher education, and K–12 programs, including language learning and culinary education. The platform is designed to help organizations understand learner progress at scale and adjust instruction, support, and program design based on evidence from real learning activities. | $5M / Series A / Jul 16, 2026 | |
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
Stealth BioTherapeutics
|
Stealth is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. | $25M / Series B / Jul 14, 2026 | |
Ampa Health
|
Ampa Health is a health technology business developing scalable brain stimulation technologies to treat depression, anxiety, and addiction. | Seed / May 14, 2026 | |
SimpliFed
|
SimpliFed is a healthcare technology company that provides virtual maternal care focused on breastfeeding and baby feeding support for families. It offers a telehealth platform that connects parents with certified lactation and baby-feeding specialists, delivering personalized, evidence-based care from pregnancy through the postpartum period. Theplatform includes services such as feeding guidance, remote monitoring, mental health screenings, and ongoing support to improve maternal and infant health outcomes. SimpliFed works closely with healthcare providers and health plans, integrating its services into existing care systems to enhance access and continuity of care. Its approach emphasizes inclusive, judgment-free support, helping parents make informed decisions about feeding methods while addressing both physical and emotional well-being. | $10.8M / Series A / Apr 07, 2026 | |
Cognito Therapeutics
|
Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $105M / Series C / Mar 05, 2026 | |
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M / Series D / Feb 05, 2026 | |
Nocion Therapeutics
|
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | |
Mira
|
Mira are audio-first smart glasses that "remember everything." | $6.6M / Seed / Nov 24, 2025 | |
|
Ampa Health
|
Ampa Health is a health technology business developing scalable brain stimulation technologies to treat depression, anxiety, and addiction. | $8.5M / Seed / Oct 22, 2025 | |
| See all 155 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Morningside invest in?
Morningside invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 155 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Morningside?
Public channels for Morningside include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Morningside?
The team at Morningside includes Gerald Chan (Co-founded), Isaac Cheng (Investment Professional) and Richard Liu (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
